Start-Up Spotlight: NovaSignal Aims To Commercialize Transcranial Ultrasound

With a mostly forgotten imaging modality, NovaSignal is trying to create the “fifth vital sign.” Medtech Insight spoke to chairman and chief executive officer, Diane Bryant, to learn more about the company's transcranial ultrasound technology.

NovaSignal's NovaGuide System
NovaSignal's NovaGuide System • Source: NovaSignal

NovaSignal, rebranded from Neural Analytics in July 2020, is trying to make transcranial ultrasound accessible and affordable for all.

When Robert Hamilton founded the company in 2013, transcranial ultrasound was a little-known technology with huge capabilities for creating real-time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diagnostic Imaging

PathAI Talks PCCPs: ‘Accelerated Software Updates, Saves Time And Money’

 

The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.

SpotitEarly Sets Up US HQ, Launches Trials For Dog- And AI-Powered Early Cancer Detection Test

 
• By 

Among early cancer screening tests, SpotitEarly stands out by combining dogs’ superior sense of smell with machine learning. SpotitEarly plans two US clinical trials for breast and lung cancer aiming to seek FDA clearance, but needs more funding to support clinical development and commercialization.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

More from Diagnostics

SpotitEarly Sets Up US HQ, Launches Trials For Dog- And AI-Powered Early Cancer Detection Test

 
• By 

Among early cancer screening tests, SpotitEarly stands out by combining dogs’ superior sense of smell with machine learning. SpotitEarly plans two US clinical trials for breast and lung cancer aiming to seek FDA clearance, but needs more funding to support clinical development and commercialization.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."